The flavonoid hydroxygenkwanin reduces inflammation and neointimal formation

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Cell Biology

Background:

• Vascular smooth muscle cell (VSMC) proliferation and migration are key drivers of neointimal hyperplasia and restenosis.
• Inflammatory cytokines like platelet-derived growth factor-BB (PDGF-BB) and tumor necrosis factor-α (TNF-α) stimulate these abnormal VSMC behaviors.
• Hydroxygenkwanin (HGK) exhibits known anti-inflammatory, antiproliferative, and antimigratory properties.

Purpose of the Study:

• To investigate the therapeutic potential of HGK in treating neointimal hyperplasia.
• To elucidate the underlying molecular mechanisms of HGK's action on VSMCs and endothelial progenitor cells (EPCs).

Main Methods:

• In vitro studies using PDGF-BB- or TNF-α-stimulated VSMCs to assess proliferation, migration, and inflammation.
• Analysis of the Phosphoinositide-dependent kinase-1 (PDK1)/AKT/mammalian target of rapamycin (mTOR) signaling pathway.
• In vitro assessment of HGK's effect on circulating EPC chemotaxis.
• In vivo mouse model of femoral artery denudation to evaluate HGK's impact on re-endothelialization and neointimal hyperplasia.

Main Results:

• HGK significantly inhibited VSMC proliferation, migration, and inflammation induced by PDGF-BB and TNF-α.
• HGK treatment modulated the PDK1/AKT/mTOR pathway in VSMCs.
• HGK enhanced the chemotaxis of circulating endothelial progenitor cells (EPCs).
• In vivo, HGK accelerated re-endothelialization and markedly reduced neointimal hyperplasia following arterial injury.

Conclusions:

• HGK demonstrates significant therapeutic effects against neointimal hyperplasia and restenosis.
• HGK's mechanism involves the regulation of the PDK1/AKT/mTOR pathway and promotion of EPC function.
• HGK holds promise as a potential therapeutic agent or functional food supplement for restenosis treatment.